Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Silibinin--a promising new treatment for cancer.

Cheung CW, Gibbons N, Johnson DW, Nicol DL.

Anticancer Agents Med Chem. 2010 Mar;10(3):186-95. Review.

PMID:
20015009
2.

Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.] Gaertn.).

Tamayo C, Diamond S.

Integr Cancer Ther. 2007 Jun;6(2):146-57. Review.

PMID:
17548793
3.

Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells.

Davis-Searles PR, Nakanishi Y, Kim NC, Graf TN, Oberlies NH, Wani MC, Wall ME, Agarwal R, Kroll DJ.

Cancer Res. 2005 May 15;65(10):4448-57.

4.

Targeting silibinin in the antiproliferative pathway.

Li L, Zeng J, Gao Y, He D.

Expert Opin Investig Drugs. 2010 Feb;19(2):243-55. doi: 10.1517/13543780903533631. Review.

PMID:
20047507
5.

Anti- and pro-mutagenic effects of silymarin in the Ames bacterial reverse mutation assay.

Kaleeswaran S, Sriram P, Prabhu D; Chinnathambi; Vijayakumar, Mathuram LN.

Phytother Res. 2009 Oct;23(10):1378-84. doi: 10.1002/ptr.2772.

PMID:
19277970
6.

Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells.

Cufí S, Bonavia R, Vazquez-Martin A, Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, Martin-Castillo B, Barrajón-Catalán E, Visa J, Segura-Carretero A, Bosch-Barrera J, Joven J, Micol V, Menendez JA.

Food Chem Toxicol. 2013 Oct;60:360-8. doi: 10.1016/j.fct.2013.07.063. Epub 2013 Aug 1.

PMID:
23916468
7.

A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer.

Flaig TW, Glodé M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su LJ, Li Y, Harrison G, Agarwal R, Crawford ED, Lucia MS, Pollak M.

Prostate. 2010 Jun 1;70(8):848-55. doi: 10.1002/pros.21118.

PMID:
20127732
8.

Advances in the use of milk thistle (Silybum marianum).

Post-White J, Ladas EJ, Kelly KM.

Integr Cancer Ther. 2007 Jun;6(2):104-9. Review.

PMID:
17548789
10.

Milk thistle.

Rainone F.

Am Fam Physician. 2005 Oct 1;72(7):1285-8. Review.

11.

Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer.

Hogan FS, Krishnegowda NK, Mikhailova M, Kahlenberg MS.

J Surg Res. 2007 Nov;143(1):58-65.

PMID:
17950073
12.

Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells.

Tyagi A, Bhatia N, Condon MS, Bosland MC, Agarwal C, Agarwal R.

Prostate. 2002 Nov 1;53(3):211-7.

PMID:
12386921
13.

Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy.

Bosch-Barrera J, Menendez JA.

Cancer Treat Rev. 2015 Jun;41(6):540-6. doi: 10.1016/j.ctrv.2015.04.008. Epub 2015 Apr 27. Review.

PMID:
25944486
14.

Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies.

Kroll DJ, Shaw HS, Oberlies NH.

Integr Cancer Ther. 2007 Jun;6(2):110-9. Review.

PMID:
17548790
15.

New therapeutic potentials of milk thistle (Silybum marianum).

Milić N, Milosević N, Suvajdzić L, Zarkov M, Abenavoli L.

Nat Prod Commun. 2013 Dec;8(12):1801-10. Review.

PMID:
24555302
16.
17.

[An updated review at molecular pharmacological level for the mechanism of anti-tumor, antioxidant and immunoregulatory action of silibinin].

Wang HJ, Jiang YY, Lu P, Wang Q, Ikejima T.

Yao Xue Xue Bao. 2010 Apr;45(4):413-21. Review. Chinese.

PMID:
21355204
18.

Future directions for research on Silybum marianum for cancer patients.

Sagar SM.

Integr Cancer Ther. 2007 Jun;6(2):166-73. Review.

PMID:
17548795
19.

Milk thistle and the treatment of hepatitis.

Giese LA.

Gastroenterol Nurs. 2001 Mar-Apr;24(2):95-7. Review.

PMID:
11847735
20.

A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer.

Singh RP, Agarwal R.

Mutat Res. 2004 Nov 2;555(1-2):21-32. Review.

PMID:
15476849

Supplemental Content

Support Center